Internal Medicine, Hematology & Oncology · Myrtle Beach, SC
NPI
1730379132
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
8121 Rourk St
Myrtle Beach, SC, 29572
Phone (843) 692-5000
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.9M
210,282 services
Medicare patients, 2024
1,003
Average age 75
Drug cost, 2024
$3.5M
1,091 prescriptions
Company payments, 2025
$1,042
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dejuania A Brown-Rawls was code J0897 (injection, denosumab, 1 mg), 15,420 times for 108 patients. In total Dejuania A Brown-Rawls billed 210,282 services in 169 codes, and Medicare paid $3.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 15,420 | 108 | $20.41 | $315K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,016 | 19 | $44.46 | $623K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 10,400 | 91 | $0.10 | $1,042 |
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 9,360 | 16 | $0.39 | $3,623 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 9,340 | 50 | $6.40 | $60K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 7,650 | 18 | $0.11 | $857 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 7,000 | 57 | $15.82 | $111K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,300 | 13 | $20.77 | $69K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,724 | 63 | $0.09 | $241 |
| 36415 Venipuncture Blood Collection | Office | 2,644 | 731 | $8.60 | $23K |
| 85025 Blood Count | Office | 2,632 | 722 | $7.59 | $20K |
| 82565 Clinical Chemistry | Office | 1,832 | 666 | $5.01 | $9,177 |
| 84520 Clinical Chemistry | Office | 1,830 | 665 | $3.86 | $7,066 |
| 82435 Clinical Chemistry | Office | 1,830 | 665 | $4.50 | $8,234 |
| 84295 Clinical Chemistry | Office | 1,828 | 665 | $4.70 | $8,590 |
By year: 2022 $4.0M for 293,672 services; 2023 $4.6M for 320,412 services; 2024 $3.9M for 210,282 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 2,644 | 731 | $8.60 | $23K |
| 85025 Blood Count | 2,632 | 722 | $7.59 | $20K |
| 82565 Clinical Chemistry | 1,832 | 666 | $5.01 | $9,177 |
| 84520 Clinical Chemistry | 1,830 | 665 | $3.86 | $7,066 |
| 82435 Clinical Chemistry | 1,830 | 665 | $4.50 | $8,234 |
| 84295 Clinical Chemistry | 1,828 | 665 | $4.70 | $8,590 |
| 80076 Clinical Chemistry | 1,819 | 666 | $7.99 | $15K |
| 82310 Clinical Chemistry | 1,815 | 665 | $5.05 | $9,162 |
| 83615 Clinical Chemistry | 1,814 | 666 | $5.91 | $11K |
| 84100 Clinical Chemistry | 1,814 | 665 | $4.64 | $8,412 |
Medicare prescription drug claims, 2024
In 2024, the drug Dejuania A Brown-Rawls prescribed most often to Medicare patients was Anastrozole, with 203 prescriptions and refills. In total Dejuania A Brown-Rawls wrote 1,091 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 203 | 544 | 67 | $5,163 |
| Lenalidomide Generic | 59 | 59 | Under 11 | $737K |
| Hydroxyurea Generic | 55 | 114 | 15 | $2,135 |
| Gabapentin Generic | 37 | 43 | 11 | $338 |
| Xarelto Rivaroxaban | 35 | 71 | Under 11 | $39K |
| Acyclovir Generic | 34 | 36 | Under 11 | $218 |
| Letrozole Generic | 31 | 83 | Under 11 | $507 |
| Omeprazole Generic | 30 | 46 | 12 | $89.3 |
| Imatinib Mesylate Generic | 30 | 32 | Under 11 | $57K |
| Ibrance Palbociclib | 27 | 27 | Under 11 | $419K |
| Prednisone Generic | 27 | 27 | Under 11 | $119 |
| Tamoxifen Citrate Generic | 26 | 78 | Under 11 | $581 |
| Imbruvica Ibrutinib | 25 | 25 | Under 11 | $399K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 24 | 24 | 16 | $417 |
| Anagrelide Hcl Generic | 22 | 28 | Under 11 | $908 |
Brand drugs: 228 claims; generic drugs: 863 claims; opioid claims: 53.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dejuania A Brown-Rawls $1,042 ($1,042 in general payments such as food, travel and fees) from 21 companies. The largest payer was Genmab U.S., Inc. with $150.
| Company | Payments | Amount |
|---|---|---|
| Genmab U.S., Inc. GMAB | 2 | $150 |
| Janssen Biotech, Inc. JNJ | 4 | $87.93 |
| Merck Sharp & Dohme LLC MRK | 3 | $81.16 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $73.2 |
| Abbvie Inc. ABBV | 4 | $67.01 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $66.16 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $54.61 |
| TerSera Therapeutics LLC | 2 | $53.73 |
| GlaxoSmithKline, LLC. GSK | 2 | $53.53 |
| Jazz Pharmaceuticals Inc. JAZZ | 2 | $46.82 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.